stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs Genmab A/S Sponsored ADR (GMAB)
- Alnylam Pharmaceuticals, Inc. ALNY 155.83 −0.53%
- Genmab A/S Sponsored ADR GMAB 53.44 +1.33%
Alnylam Pharmaceuticals, Inc. and Genmab A/S Sponsored ADR are both Biotechnology companies. Genmab A/S Sponsored ADR is the larger, with a market value of $31.5B against $21.0B — 1.5× the size. Alnylam Pharmaceuticals, Inc. trades at the lower P/E: 7.9× against 41.7×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against 22.3%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs 19.1%) and the higher return on invested capital (59.4% vs 6.99%). Across the 21 metrics below, Alnylam Pharmaceuticals, Inc. leads on 17 and Genmab A/S Sponsored ADR on 4.
Valuation
Profitability
| Metric | ALNY | GMAB | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 93.03% | 65.16% |
| Operating margin | 19.50% | 25.95% | 0.00% |
| Net margin | 52.85% | 19.08% | 0.00% |
| Free cash flow margin | 16.08% | (153.64%) | 0.00% |
| Return on equity | 138.07% | 14.00% | (50.12%) |
| Return on assets | 41.25% | 8.30% | (45.60%) |
| Return on invested capital | 59.37% | 6.99% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack